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Available online 9 December 2016Interleukin-27 (IL27) is a type-I-cytokine of the IL6/IL12 family predominantly secreted by activated macro-
phages and dendritic cells. In the liver, IL27 expression was observed to be upregulated in patients with hepatitis
B, and sera of hepatocellular carcinoma (HCC) patients contain signiﬁcantly elevated levels of IL27 compared to
healthy controls or patients with hepatitis and/or liver cirrhosis. In this study, we show that IL27 induces STAT1
and STAT3 phosphorylation in 5HCC lines and 3 different types of non-transformed liver cells.Wewere especial-
ly interested in the relevance of the IL27-induced STAT3 activation in liver cells. Thus, we compared the IL27 re-
sponses with those induced by IFNγ (STAT1-dominated response) or IL6-type cytokines (IL6, hyper-IL6 (hy-IL6)
or OSM) (STAT3-dominated response) by microarray analysis and ﬁnd that in HCC cells, IL27 induces an IFNγ-
like, STAT1-dependent transcriptional response, but we do not ﬁnd an effective STAT3-dependent response. Val-
idation experiments corroborate the ﬁnding from the microarray evaluation. Interestingly, the availability of
STAT1 seems critical in the shaping of the IL27 response, as the siRNA knock-down of STAT1 revealed the ability
of IL27 to induce the acute-phase proteinγ-ﬁbrinogen, a typical IL6 family characteristic.Moreover,we describe a
crosstalk between the signaling of IL6-type cytokines and IL27: responses to the gp130-engaging cytokine IL27
(but not those to IFNs) can be inhibited by IL6-type cytokine pre-stimulation, likely by a SOCS3-mediated mech-
anism. Thus, IL27 recapitulates IFNγ responses in liver cells, but differs from IFNγ by its sensitivity to SOCS3
inhibition.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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SOCS31. Introduction
The primary source of Interleukin-27 (IL27) - a type-I-cytokine - are
activatedmacrophages and dendritic cells. Best described are the effects
of IL27 on T-cells and on innate immune cells [1,2]. Although IL27 can
have pro-inﬂammatory effects, other studies also suggest that IL27 is
immunosuppressive [3,4]. IL27 was shown to promote TH1 responses
via the induction of the transcription factors T-bet, upregulation of
IL12Rβ2 and of interferon-γ (IFNγ) production [5–8]. Suppression ofring), andreas_zimmer@web.de
nns), elisabeth.letellier@uni.lu
@lih.lu (P.V. Nazarov),
A. Ginolhac), serge.haan@uni.lu
an@uni.lu (C. Haan).
. This is an open access article underthe TH2 responses was also reported [7]. However, IL27 is also capable
to suppress both TH1 and TH2 responses during infectionwith a variety
of pathogens [9–11]. To date,most studies have focused on the effects of
IL27 on immune cells, whereas the action on other cell types is less well
studied.
IL27 can be grouped into the IL6/IL12 superfamily of cytokines [5].
The heterodimeric IL27, composed of the two non-covalently linked
subunits p28 and EBI3 (Epstein-Barr virus induced gene 3) [5], is related
to the heterodimeric cytokines IL12 and IL23, in which the two subunits
are, however, covalently linked. IL27 signals via a receptor complex
composed of the IL27-speciﬁc receptor chain WSX1 [5] and the com-
mon receptor subunit of IL6-type cytokines, gp130 [12]. It is thus also
closely related to the IL6-type subfamily of cytokines.
IL27 expression was observed to be upregulated in patients with
hepatitis B [13–16]. Hepatocellular carcinoma (HCC) patients contain
signiﬁcantly elevated levels of IL27 compared to healthy controls or pa-
tients with hepatitis and/or liver cirrhosis [15,16]. HCC is a type ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is associated with a good prognosis, with type I interferons, IFNγ and
IL12 being crucial for immune rejection of HCC [17]. We previously re-
ported interferon-γ-like antiviral activity of IL27 in hepatic cells [18,
19]. IL27 inhibits the replication of hepatitis B virus (HBV) and hepatitis
C virus (HCV) in HCC cell lines [14,20], induces further interferon ex-
pression in HCC cells and dendritic cells (DC) [14] and has been de-
scribed to be produced by plasmacytoid dendritic cells of the liver [21].
In immune cells, IL27was reported to promote its cellular responses
via STAT1 and STAT3 [7–9,22].Wehave previously described phosphor-
ylation of both STAT1 and STAT3 upon IL27 stimulation in hepatic cells,
although the responses we observed so far are typically associated with
a STAT1 response. Thus, we set out to investigate the IL27-induced
STAT3 activation and its downstream targets inHCC cells.We compared
the IL27 responseswith those induced by IFNγ (STAT1 response) or IL6-
type cytokines (IL6, hyper-IL6 (hy-IL6) or OSM) (STAT3 response). We
ﬁnd that in hepatocytes IL27 induces an IFNγ-like, STAT1-dependent
transcriptional response, whereas a STAT3 response is not observed. In
contrast to responses to IFNγ, however, IL27 responses are inhibited
by IL6-type cytokine pre-stimulation, through a SOCS3-mediated
mechanism.
2. Material and methods
2.1. Materials and cell culture
All cells were grown at 37 °C in a water-saturated atmosphere at 5%
CO2. HepG2, Hep3B, Huh7, PH5CH8, HLE, HLF cells were maintained in
DMEM medium (Sigma) supplemented with 10% fetal bovine serum
(PAA), 100 μg/L streptomycin and 60 mg/L penicillin (Lonza) and
25 mM HEPES (Lonza). “Upcyte”-hepatocytes (genetically engineered
human primary hepatocytes) were cultured in Upcyte hepatocyte me-
dium as recommended by the supplier (Medicyte). SV40 large T
antigen-immortalized normal human liver epithelial cells (THLE2)
were cultured in LHC-8 medium supplemented with 70 ng/mL
phosphoethanolamine, 5 ng/mL epidermal growth factor, 10% FBS,
100 mg/L streptomycin, 60 mg/L penicillin.
The gp130, STAT1, STAT3 SMARTpool siGENOME siRNAs and the
siGENOME non targeting siRNA pool #2 were obtained from
Dharmacon. WSX1 silencer select siRNA (s18137 and s18138) and Si-
lencer Select Negative Control no.1 siRNA were purchased from Life
Technologies. siRNA reverse transfections were performed using Lipo-
fectamine RNAiMAX (Life Technologies) and 10–20 nM of siRNA ac-
cording to the manufacturer's protocol. Cells were stimulated 24–48 h
after transfection.
Cytokines were used according to their molecular weight, so that
stimulation occurs at comparable molar concentrations. Cells were
stimulated with 20 ng/mL human recombinant OSM, IL6, IFNγ or IFNα
(Peprotech), 50 ng/mL IL27 (R&D systems) or 40 ng/mL of hyper-IL6
(a kind gift of Prof. Stefan Rose-John, University of Kiel, Germany) ex-
cept if stated otherwise in the ﬁgure legends.
2.2. Cell lysis and Western blot analysis
Cell lysis was performed as described before [23]. Proteinswere sep-
arated by SDS-PAGE, followed by electro-blotting onto a PVDF mem-
brane (PVDF-PSQ or PVDF-FL, Millipore). The following antibodies
were used: STAT3 (BD Biosciences Cat# 610190, RRID:AB_397589),
pSTAT1 (BD Biosciences Cat# 612233, RRID:AB_399556), STAT1 (BD
Biosciences Cat# 610116, RRID:AB_397522), pSTAT3 (Santa Cruz Bio-
technology Cat# sc-32293, RRID:AB_628412), γﬁbrinogen (Millipore
Cat# 05-760, RRID:AB_11211422), actin (Millipore Cat# MAB1501,
RRID:AB_2223041), pSTAT3 (Cell Signaling Technology Cat# 9145S,
RRID:AB_561305), TAP2 (Cell Signaling Technology Cat# 12259
RRID:AB_2619687), JunB (Cell Signaling Technology Cat# 3753S,
RRID:AB_2130002), Vinculin (Abcam Cat# ab18058, RRID:AB_444215). HRP-conjugated secondary antibodies were purchased from
Cell Signaling. Signals were detected using an ECL solution containing
2.5 mM luminol, 2.6 mM hydrogen peroxide, 100 mM Tris/HCl pH 8.8
and 0.2mMpara-coumaric acid [24] and a CCD camera system (BioRad)
or an Odyssey Infrared Imaging System (Li-COR Biosciences) using
IRDye 680RD anti-rabbit IgG and IRDye 800CWanti-mouse IgG. Quanti-
tation was performed on single channels with the analysis software
Image Studio Lite V4.0 provided by LI-COR Biosciences (Lincoln, NE,
USA). Brieﬂy, the signals to be quantitated were normalized with re-
spect to the loading control for each lane. Each normalized signal was
then divided by the mean of all normalized signals of one membrane
to adjust for the possible variation of signal intensity between different
membranes (each membrane including one biological replicate). The
signal intensity was then represented as % of a speciﬁc signal as de-
scribed in the corresponding ﬁgure legends.
2.3. Quantitative PCR
Total RNA was extracted using the NucleoSpin RNA II kit (Macherey
Nagel) according to the manufacturer's instructions. 1 μg of total RNA
was reverse-transcribed with the iScript cDNA synthesis kit (BioRad)
in a volume of 20 μL according to the manufacturer's instructions.
Real-time PCR detection was carried out on a CFX96 Detection System
(BioRad) using 200 ng RNA input in a 10 μL reaction volume, 2 x iTaq
SYBR Green Supermix (BioRad) and 5 pmol gene-speciﬁc primer pairs
(SOCS3-F (ATGAGAACTGCCAGGGAATC), SOCS3-R (CCCAGGCTCCACAA
CCA), WSX1-F (GCATCCTATTCTTGTGGGG), WSX1-R (CACTTTGTGCC
TTAGGTGGT), gp130-F (TGAAACTGCTGTGAATGTGG), gp130-R (CATC
CTTCCCACCTTCATCT), Eurogentec). Speciﬁcity of the qPCR primers
was assessed by a post-qPCR melting curve analysis. Cq values for
mRNAs were normalized to 3 reference genes: TBP (TATA binding pro-
tein), HPRT1 (hypoxanthine phosphoribosyltransferase 1) and PPIA
(peptidylprolyl isomerase A). Based on the geometric mean of the
three reference genes, a normalization factor was calculated for each
sample using geNorm [25], a VBAapplet forMicrosoft Excel. The relative
amount of each target in each sample was then corrected by dividing its
amount by the corresponding normalization factor. Fold changes were
calculated by dividing the normalized relative amount of treated sam-
ples with the normalized relative amount of the control sample.
2.4. Reporter gene assays
Cells were reverse transfected on a 96 well plate with 0.1–0.2 μg of
the respective reporter gene construct using Lipofectamine LTX&PLUS
or Lipofectamine 2000 (Life Technologies) transfection reagent for
HepG2 or Huh7 cells, respectively. 24 h after transfection, cells were
stimulated for 24 h as described in the ﬁgure legends. Supernatants
were discarded and cells were lysed using 20 μL lysis buffer. Lysis and
luciferase assay was carried out as described [26]. Experiments were
performed at least in biological triplicates, each with 3 technical repli-
cates. The STAT3-speciﬁc luciferase reporters, pXP2d2-rat pancreatitis-
associated protein 1 (rPAP1) [27] and pGL3-Hepcidin [18] were de-
scribed earlier. The pGAS-TA-luc and pISRE-TA-luc plasmids were
from Clontech. pcDNA5-FRT-TO-V5-SOCS3 (pcDNA5-SOCS3) was gen-
erated by inserting PCR ampliﬁed SOCS3 into pcDNA5-FRT-TO-V5
using BamHI and NheI restriction sites. Empty pcDNA5-FRT-TO-V5 was
used as negative control.
2.5. Flow cytometry
Cells were re-suspended in cold PBS supplemented with 5% FBS and
0.1% sodium azide (PBS/azide) and incubated with anti-HLA-ABC-PE
(MHC1, Immunotools, Cat# 21159034, RRID: AB_2629494), anti-
gp130 (BD Biosciences Cat#555757, RRID: AB_396098), anti-WSX-1
(R and D Systems Cat# FAB14791P, RRID:AB_10718687) or the corre-
sponding IgG control antibody for 1 h at 4 °C. Cells were then washed
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using FACSDiva (BD Biosciences) software. Overlays were created
using FlowJo software.
2.6. Whole genome microarray analysis
HepG2, Hep3B, Huh7, HepG2-shScr and HepG2-shSTAT3 cells were
left untreated or were stimulated with hyper-IL6, OSM, IFNγ or IL27 for
24 h. Total RNAwas extracted using the using themiRNeasy kit (Qiagen).
For each treatment, two independent biological replicateswere analyzed.
Only high quality RNAs were used with a ribosomal RNA ratio N1.9 and
no evidence of degradation, as evaluated using the Agilent Bioanalyzer
2100 RNA 6000 nanoassay. All samples had a RIN number N8. Gene ex-
pression proﬁling experiments were performed using the Affymetrix
HTA v.2.0 arrays according to the GeneChip®WT PLUS Reagent Kit, Man-
ual Target Preparation for GeneChip®Whole Transcript (WT) Expression
Arrays P/N 703174 Rev.2 2013 protocol. 100 ng of total RNA was used as
starting amount for microarray experiments.
Microarray data were normalized and summarized to gene level by
RMA [28] algorithm with GC correction in Partek® Genomics Suite®
software, v. 6.6. In order to remove uninformative features, only genes
with a log2 expression level above 5 in at least one sample were consid-
ered for further analysis. Statistical analysiswas performed in R [29] and
using linear models in an empirical Bayesian approach implemented in
the R/Bioconductor package limma [30]. A global linear model account-
ing for cell lines (HepG2, Huh7, Hep3B or HepG2-shScr, HepG2-
shSTAT3) and treatments (IL27, IFNγ, hy-IL6, OSM) was ﬁt, and then
p-values were estimated for various contrasts. P-values were adjusted
for multiple comparison by Benjamin-Hochberg's FDR method [31]
and genes with FDR b 0.05 were selected. Volcano plots and heatmaps
were drawn using the R package ggplot2 [32].
2.7. Statistical analysis
Representative data are shown and are expressed as the mean ±
standard deviation. For statistical analysis (described in detail for the
different ﬁgures below) the error probabilities b0.05 were considered
to be signiﬁcant, ***P b 0.001, **P b 0.01, *P b 0.05.
For Fig. 4, one-way ANOVAwith Dunnett's post-test was performed
using GraphPad InStat version 3.10 (GraphPad Software, San Diego
California USA, www.graphpad.com).
To test for statistical signiﬁcance in Fig. 6B we used two-samples t-
tests to compare all conditions. To adjust for unequal variances, the
Welch correction was applied. For 9 data points per sample, the expect-
ed number of degrees of freedom is 16, the Welch corrected degrees of
freedom (df) are reported below. Finally, correction for multiple testing
was done using the p.adjust R base functionwith default parameters, i.e.
Benjamini & Hochberg method. Computation was performed using R
[29] with the packages tidyverse [33] and broom [34]. Luciferase activity
is signiﬁcantly upregulated upon IL27 stimulation in all conditions and
cell lines (P b 0.001). This is not indicated in Fig. 6B. On the other
hand, the analysis shows that the reduction of luciferase activity due
the SOCS3 expression is highly signiﬁcant compared to the empty vec-
tor control. The results of this latter analysis are indicated in Fig. 6B.
3. Results
3.1. In HCC cell lines and hepatocytes, IL27 induces a STAT1/STAT3 phos-
phorylation pattern which is more similar to responses generated by inter-
ferons than to those generated by IL6-type cytokines
Since it is unclear if the STAT3 phosphorylation elicited by IL27 leads
to an upregulation of proteins associated with a STAT3 transcriptional
response in hepatocytes, we set out to investigate this potential activity
of STAT3 upon IL27 stimulation.We began by assessing the phosphorylation of STAT factors activated
by the cytokines IL6, hyper-IL6 (hy-IL6), OSM, IL27, IFNγ and IFNα by
comparative Western blot analyses. The 5 hepatocellular carcinoma
(HCC) cell lines (HepG2, Hep3B, Huh7, HLE, HLF) and the non-cancer
immortalised hepatocytes (PH5CH8, THLE2, hepatocytes (Upcyte)) all
reacted to IL27 with a robust phosphorylation of STAT1 and a phosphory-
lation of STAT3, the latter being only slightly over background for some of
the cell lines (Fig. 1A/B andSupplemental Fig. 1A). Someof thehepatic cell
lines were unresponsive or only weakly responsive to IL6. Since stimula-
tion with hyper-IL6 (hy-IL6), a synthetic fusion protein of IL6 and the sol-
uble form of the IL6Rα (gp80) mimicking IL6/sgp80 responses, restored
STAT signalling in the IL6-unresponsive cell lines, we conclude that the
IL6 unresponsiveness is due to low expression of the membrane-bound
form of the IL6Rα (Supplemental Fig. 1A). Hep3B cells did not respond
to OSM stimulation (Fig. 1A). This was due to the absence of the OSM-
speciﬁc signalling receptor OSMR, as we could show by ﬂow cytometry
and aswas described by others already [35]. The Jak/STAT signalling path-
way was induced in all tested cells stimulated with IFNγ and IFNα.
In general, a qualitative comparison of the signals induced by the dif-
ferent cytokines shows that STAT1 phosphorylation by IL27 is robust,
comparable to IFNγ and IFNα which are strong STAT1 activators. On
the other hand, phosphorylation of STAT3 upon IL27 stimulation was
generally lower than the one induced by strong STAT3 activators such
as IL6, hyper-IL6, or OSMand even generally lower than the one induced
by IFNα. In addition, we found STAT1 phosphorylation upon OSM and
IL6 to be transient over time, while STAT3 phosphorylation was
sustained. For IL27 the observed STAT1 and STAT3 phosphorylation
both seemed to be both stable over time (Supplemental Fig. 1B/C).
IL27 also induced STAT1 protein expression, as did IFNγ, while IL6 or
OSM did not show this response (Fig. 1B and Supplemental Fig. 1B/C).
Thus, we conclude that in all hepatic cell lines tested, IL27 induces an
interferon-like robust STAT1 phosphorylation while STAT3 seems to
be phosphorylated to a lesser extent than by IL6-type cytokines (IL6,
hy-IL6, OSM). Nevertheless, the STAT3 phosphorylation response upon
IL27 is sustained and may lead to gene transcription.
3.2. The cytokine receptor system used by IL27 in hepatic cells also consists
of gp130 and WSX1
To check that the receptor system used by IL27 is identical to the one
described in the hematopoietic system, we used siRNA against gp130
andWSX1. Knock-down of gp130 orWSX1 in HepG2 cells led to an ab-
rogation of IL27 signalling and prevented STAT1 protein upregulation
(Fig. 1C/D). We also investigated cell surface expression of gp130 and
WSX1 by ﬂow cytometry on HepG2, Huh7 and Hep3B cells. All cell
lines showed expression of the receptors on the cell surface (Fig. 1E).
Thus, IL27 is using its canonical receptor system composed of gp130
and WSX1 also in hepatic cell lines.
3.3. Whole genome microarray analysis of IL27 responses shows little
overlap with responses to IL6-type cytokines but close resemblance to an
IFNγ response
Our aim was to compare the IL27 response to those of the other cy-
tokines. For thiswe ﬁrst focused our transcriptome analyses on compar-
ing the number of genes speciﬁcally regulated by each cytokine alone
(IL27, IFNγ, OSM, or hy-IL6) and the number of genes commonly regu-
lated by the different treatments (Fig. 2A and Supplemental Fig. 2). For
all three cell lines (HepG2, HuH7, Hep3B) there is a minor number of
genes regulated by all four or at least three of the treatments. These
genes, which obviously are STAT-regulated but have no preference for
STAT1 or STAT3, were not considered for our analysis. In general, for
all cell lines the number of genes regulated commonly by IFNγ and
IL27 was very high and few genes were regulated by IL27 only (0–6).
In Huh7 cells, for example, where IL27 and IFNγ regulate an
approximatively similar number of genes, the overlap between the
AB
C
E
Fig. 1. Responses of hepatocellular carcinoma cells and hepatocytes to different cytokine stimuli. A) HepG2, Hep3B and Huh7 hepatocellular carcinoma cell lines were stimulated with
cytokines for one hour and lysates were analyzed by Western Blot immunodetection. Phosphorylation of STAT factors (pSTAT3 and pSTAT1), STAT3, STAT1 and actin was monitored.
Representative blots of three biological replicates are shown. B) HepG2 and hepatocytes (Upcyte) were stimulated with cytokines as indicated and lysates were analyzed by Western
Blot immunodetection for phosphorylation of STAT factors (pSTAT3 and pSTAT1) and changes in STAT1 protein expression. Tubulin detection served as loading control. A
representative blot of three biological replicates is shown. C) HepG2 were transfected with siRNA against gp130 or WSX1 and the corresponding scrambled control (siScr). Before lysis,
cells were stimulated for 6 or 24 h with IL27. Cells were lysed 48h after transfection. The Western blot was probed with antibodies against pSTAT1, STAT1 and tubulin. A
representative blot of three biological replicates is shown. D) The efﬁciency of down-regulation of WSX1 and gp130 mRNA in HepG2 was assessed by quantitative PCR 48h after
transfection of the siRNA. Standard deviations are calculated from three biological replicates. E) HepG2, Hep3B and Huh7 were analysed for gp130 and WSX expression by Flow
cytometry. Overlays comparing speciﬁc antibody versus control antibody shifts are shown.
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speciﬁcally regulated only by IL27 (0) or IFNγ (23) (Fig. 2A). Thus, the
IL27 and IFNγ responses seem very similar. On the other hand, there
are very few co-regulated genes when comparing IL27 or IFNγ to IL6
and OSM, while IL6 and OSM again co-regulate many genes (Fig. 2A/B,
Supplemental Figs. 2 and 3, see also Supplemental Tables 1–4 for lists
of regulated genes). Ingenuity pathway analysis conﬁrmed that IFNγand IL27 activate the same downstream canonical pathways but did
not uncover new functions of IL27 that are different from the ones of
IFNγ (Data not shown).
Fig. 2C and Supplemental Fig. 4A showvolcanoplots inwhich a set of
IFNγ-regulated genes (in blue) and IL6-regulated genes (in red) are
highlighted. The list of validated genes is based on previously published
studies and is shown in Supplemental Fig. 4B/C [36–41]. The volcano
AB C
Fig. 2.Microarray analysis of hy-IL6, OSM, IL27 and IFNγ responses in Huh7 cells. A) Graph showing the number of differentially expressed genes upon cytokine treatment, as well as the
number of differentially expressed genes that are unique for each cytokine, or common for two or more cytokines. The horizontal bars show the number of differentially expressed genes
(|logFC|≥1, p-value b0.05) upon OSM, IL27, IFNγ, and hy-IL6 stimulation, as compared to the non-stimulated control. The vertical bars indicate the number of genes that are uniquely
regulated by each cytokine (●), and the number of genes that are regulated by two (●–●), three (●–●–●), or all four cytokines (●–●–●–●), and that for all cytokine combinations.
As an example, 68 genes are only regulated by OSM, 0 genes are regulated by IL27 alone, and 38 genes are regulated by all four cytokines. B) A heatmap summarizing the microarray
analysis for Huh7. Shown are genes that are differentially regulated by at least two of the four cytokines (logFC|≥1, p-value b0.05). C) Volcano plots showing the regulation of a set of
validated IL6 (red) and IFNγ (blue) target genes, upon OSM, IL27, IFNγ, and hy-IL6 treatment in Huh7.
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IFNγ, while it shows little resemblance to the one of IL6 or OSM.
3.4. On the protein level, IL27 stimulation initiates an IFNγ-like response in
HCC cell lines and hepatocytes
A number of STAT1-dependent gene readouts were validated to be
upregulated upon IL27 stimulation on the protein level in a number of
HCC cell lines (HepG2, Hep3B, Huh7) and in immortalised hepatocytes(hepatocytes fromUpcyte, PH5CH8). STAT1, Tap2 andMHCIwere clear-
ly upregulated upon IL27 and IFNγ treatment, while they were not reg-
ulated by OSM (Fig. 3A and B).
3.5. IL27 stimulation does not lead to STAT3-dependent responses in HCC
cells
We next investigated the expression of STAT3-dependent genes
upon IL27 stimulation in HepG2 cells. IFNγ or hy-IL6 stimulation was
AB
Fig. 3. IL27 stimulation ofHCC cells andhepatocytes leads to an IFNγ-like response. A)A panel ofHCC cells andhepatocyteswas stimulated for 24hwithOSM, IL27or IFNγ or left untreated.
Lysates were analyzed by Western blot immunodetection using antibodies against the STAT1 target genes Tap2 and STAT1. Vinculin detection was performed to show equal loading.
Representative blots of three biological replicates are shown. B) Hepatic cell lines were stimulated for 24h with OSM, IL27 or IFNγ or left untreated. STAT1-dependent enhanced
surface expression of MHCI was investigated by ﬂow cytometry after incubation of the cells with a PE-labeled anti-MHCI antibody. Representative results of three biological replicates
are shown.
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genes γ-ﬁbrinogen and JunB were upregulated at the protein level upon
hy-IL6 stimulation but not upon IL27 or IFNγ stimulation (Fig. 4A).
SOCS3 mRNA was only slightly and transiently upregulated upon IL27
and IFNγ stimulation, while a much stronger and prolonged upregulation
became evident for the known SOCS3 regulators hy-IL6 andOSM(Fig. 4B).
In addition, IL27 stimulation did not induce expression of γ-ﬁbrinogen in
HepG2, Hep3B or Huh7 cells, in contrast to hy-IL6 treatment. IL27 on the
other hand induced expression STAT1, a known auto-regulated STAT1-
dependent gene which was not induced by hy-IL6 (Fig. 4C).
To further investigate whether IL27 can induce transcriptionally active
STAT3 homo-dimeric complexes we used two reporter gene constructs.
Both show an efﬁcient induction upon STAT3 homodimer binding and
can be used as STAT3 sensitive probes. HepG2 and Huh7 cells were
transfected with reporter plasmids containing the STAT3-dependent
promotors of rPAP1 or hepcidin andwere then stimulatedwith cytokines.
Luciferase activity was strongly induced by OSM and hy-IL6, while IFNγ
and IL27 did not signiﬁcantly induce the reporter genes (Fig. 4D). Thus,
we conclude that although IL27 leads to phosphorylation of both STAT1
and STAT3, the protein expression of known STAT3 target genes was not
observed and STAT3-speciﬁc reporter genes were not induced.
3.6. Revealing the hidden IL6-like character of IL27: STAT1 availability
orchestrates the IL27 signaling output
We then investigated the effects of a suppression of STAT1 or STAT3
expression on the inducibility of their target genes. STAT1 siRNA knock
down had different repercussions on the actions of IL27, IFNγ and hy-IL6 (Fig. 5). For IFNγ (which does not induce phosphorylation of
STAT3) knock-down of STAT1 only leads to a marginal upregulation of
γ-ﬁbrinogen even in untreated cells, while a STAT3 knock-down has
no effects on STAT1 gene expression. For IL27, on the other hand,
STAT1 knock-down led to amarkedly increased STAT3 phosphorylation
and an IL27-mediated expression of γ-ﬁbrinogen. Knock-down of
STAT3 had little repercussion on STAT1 protein levels upon IL27 stimu-
lation. Thus, knock-down of STAT1 is sufﬁcient to transform the IFNγ-
type response of IL27 into an IL6-type response, while STAT3 knock
down has little effects on IL27-induced STAT1 upregulation. In contrast,
for hy-IL6, STAT3 knock-down led to a markedly increased STAT1 phos-
phorylation and an hy-IL6-dependent expression of STAT1, while
knock-down of STAT1 had little repercussion on the γ-ﬁbrinogen ex-
pression. Thus, knock-down of STAT3 is sufﬁcient to transform the hy-
IL6 response into an IFNγ-type response, as was observed before by
others [42].
Considering the aforementioned effects we performed microarray
analysis in stably transfected HepG2 cells expressing either a scrambled
shRNA (HepG2-shScr) or a STAT3 shRNA (HepG2-shSTAT3) [43]. In the
cells stably expressing the shRNA against STAT3, STAT3 protein is efﬁ-
ciently down-regulated (Supplemental Fig. 6A). Upon IL6-type cytokine
stimulation only a residual STAT3 phosphorylation is observed while
STAT1 phosphorylation is prolonged, which also leads to a STAT1 pro-
tein upregulation (Supplemental Fig. 6A). Thus those stable shRNA
transfectants show the same effects upon cytokine stimulation than ob-
served upon STAT3 down-regulation by siRNA as shown in Fig. 5.
Analysis of the microarray data of those cells revealed that STAT3
down-regulation did not change the expression pattern of the IL27-
AC
D
B
Fig. 4. IL27 stimulation does not induce an IL6-like response inhepatocellular carcinoma cells. A)HepG2 cellswere treated for 1, 4, 6, or 8hwith IFNγ, IL27 or hyper-IL6.Western blotswere
probedwith antibodies against pSTAT1, pSTAT3, γ-ﬁbrinogen, JunB, tubulin or vinculin. Representative blots of three biological replicates are shown. B) HepG2 cells were treated for 2 or
24h with cytokines as indicated. RNA was extracted and SOCS3 levels were analyzed by quantitative PCR. Standard deviations were calculated from 3 biological replicates. Statistical
analysis was performed as decribed in materials and methods. **: P b 0.01 C) HepG2, Hep3B and Huh7 cells were treated for 2, 8, or 48h with IL27 or hyper-IL6. Western blots were
probed with antibodies against STAT1, γ-ﬁbrinogen, STAT3 or tubulin. Representative blots of three biological replicates are shown. D) HepG2 or Huh7 cells were transfected with the
rPAP1 or hepcidin luciferase reporter plasmid. 24h after transfection, cells were stimulated with hyper-IL6, OSM, IFNγ or IL27 for 24h before lysates were prepared and luciferase
activity was measured. Representative results of 3 biological replicates – each performed in technical triplicate - are shown. Standard deviations are calculated from 3 technical
replicates. Statistical analysis was performed as decribed in materials and methods. **: P b 0.01.
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found upregulation of STAT1-dependent genes in these cells; its re-
sponse was largely identical to the IFNγ and IL27 responses. Only a
few genes regulated by IL6 in parental cells were still regulated in the
shSTAT3 cells (Supplemental Fig. 5 and Supplemental tables 5 and 6).
Thus, interestingly, the residual STAT3 phosphorylation observed
upon hy-IL6 treatment in HepG2-shSTAT3 cells (corresponding to 9–
11% of the hy-IL6 signal observed in HepG2-shScr) still leads to upregu-
lation of a few IL6 regulated genes (in spite ofmostly upregulating Inter-
feron genes) while the STAT3 phosphorylation observed upon IL27 in
HepG2-shScr (corresponding to 19–35% of the hy-IL6 signal observed
in HepG2-shScr) does apparently not lead to “IL6-type” transcriptional
changes (Supplemental Figs. 5A and 6B). This might suggest that the
IL27-induced STAT3 responses are actively suppressed by a yet un-
known mechanism.
3.7. IL27 responses are suppressed by IL6-type cytokine pre-stimulation
IL27 is using its canonical receptor system composed of gp130 and
WSX1 for signalling in hepatic cell lines, while it does not upregulate
SOCS3 efﬁciently, compared to hy-IL6 or OSM (Fig. 4B). Since SOCS3 is
described to bind gp130 on phosphorylated tyrosine 759 and to nega-
tively regulate kinase activity of Jak1 [44], we hypothesised that IL6 orOSM pre-stimulation could lead to an attenuation of IL27-induced sig-
nalling events. HCC cell lines were pre-stimulated with OSM, hy-IL6 or
IL6 for 4 h before IL27, IFNα or IFNγ stimulation. After 28 (OSM, hy-IL6
or IL6) respectively 24 (IL27, IFNγ, IFNα) hours of stimulation, STAT1pro-
tein upregulation was analysed. IL27-dependent STAT1 protein expres-
sion was reduced efﬁciently if OSM, hy-IL6 or IL6 pre-stimulation had
occurred (Fig. 6A). The down-regulation observed upon IL6 pre-
stimulationwas less pronounced but in agreement with the reduced sig-
nal strength observed for IL6 compared to OSM and hy-IL6 in the respec-
tive cell lines (Fig. 6A and Supplemental Fig. 1B). The effect was not at all
observed in Hep3B cells upon OSM stimulation since they do not express
the OSMR. IFNγ- or IFNα-induced STAT1 expression was not efﬁciently
inhibited by IL6-type cytokine pre-stimulation.
To show that the IL6-type cytokine-mediated down-regulation can
bemediated by SOCS3, we co-transfected a SOCS3 expression vector to-
gether with a vector containing a STAT1 responsive (GAS or ISRE) lucif-
erase reporter gene, and stimulated the transfected cellswith IL27 to see
if SOCS3 expression is sufﬁcient to suppress the IL27-mediated STAT1
transcriptional activity. In cells transfected with the SOCS3 plasmid,
the GAS element-dependent luciferase activity was efﬁciently down-
regulated in comparison to cells which were transfected with empty
vector control (Fig. 6B). For ISRE sequence-containing reporter gene
plasmids comparable results were observed.
Fig. 5. In the absence of STAT1 expression IL27, in contrast to IFNγ, induces STAT3-
dependent gene expression. HepG2 cells were transfected with siRNA against STAT1,
STAT3 or with a scrambled control as described in materials and methods. The cells
were stimulated with IFNγ, IL27 or hy-IL6 as indicated. Western blots were probed with
antibodies against pSTAT1, pSTAT3, STAT1, STAT3, γ-ﬁbrinogen or tubulin.
Representative blots of three biological replicates are shown.
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that, in contrast to IFNγ, IL27 responses are susceptible to SOCS3 inhibi-
tion, and thus to cross-inhibition by pro-inﬂammatory IL6-type cyto-
kine signalling (Fig. 7).
4. Discussion
In the present studywe have compared the signal transduction of IL-
27 in liver cells to the one of interferons and IL6-type cytokines. We
show that (i) IL27 elicits a STAT1-dominated response and shares the
majority of target genes with IFNγ. STAT3 becomes phosphorylated, al-
beit to a weaker extent than in response to IL-6-type cytokines, but this
does not lead to a transcriptional response. (ii) IL-27 can induce STAT3
target genes only when STAT1 expression is lowered. (iii) IL-27 signal-
ing, in contrast to IFN signaling, can be attenuated by pre-stimulation
of liver cells with IL-6-type cytokines.
Using ﬂow cytometry and siRNA approaches we showed that IL27
uses its canonical receptor complex (gp130/WSX1) [45] for signaling
in hepatic cells (Fig. 1C and D). HepG2, Hep3B, Huh7, HLE, HLF,
PH5CH8, THLE2 and hepatocytes (Upcyte) all reacted to IL27 with a ro-
bust phosphorylation of STAT1 (comparable to IFNγ and IFNα re-
sponses) and a phosphorylation of STAT3, the latter being weaker
compared to the OSM, hy-IL6 or even IFNα responses in the same
cells (Fig. 1 and Supplemental Fig. 1). It is intriguing that the STAT1
SH2 domain recognition motif (YEKH) in WSX1, which closely resem-
bles the IFNγR1 Y440 (YDKP) motif, mediates STAT1 activation byIL27 so efﬁciently [46], while the 4 STAT3 recruiting tyrosines [47–50]
in gp130 lead to a less efﬁcient activation of STAT3. Nevertheless, the
STAT3 phosphorylation is sustained over time and, thus, STAT3-
dependent transcription might occur upon IL27 stimulation. Indeed,
studies in immune cells have discussed a role of STAT3 in transcriptional
responses through IL27 [46,51,52].
To better understand the STAT3 contribution to IL27 responses in
HCC we ﬁrst performed whole genome microarray analysis in 3 HCC
cell lines (HepG2, Hep3B and Huh7). We compared the transcriptional
responses of IL27 to the ones of IFNγ, hyper-L6 and OSM (OSM was
not studied in Hep3B since the OSMR is not expressed [35]) after 24 h
of stimulation. IFNγ, hyper-IL6 and OSM were used because they are
bona ﬁde activators of STAT1 (IFNγ) [53–56] and STAT3 (hyper-IL6,
OSM) [39,40,57,58] responses in HCC cells. Evaluation of the genome
microarray analysis of IL27 responses showed that there was little over-
lap with responses through IL6-type cytokines but that the IL27 re-
sponse closely resembled an IFNγ response.
Validation experiments (Figs. 3 and 4) on mRNA level (SOCS3) as
well as on the protein level (STAT1, Tap2, MHCI, γ-ﬁbrinogen, JunB)
and using speciﬁc STAT3-responsive promotor constructs (rPAP,
hepcidin; as a STAT3 homodimer-sensitive probe), led us to conclude
that although IL27 leads to sustained phosphorylation of STAT3, neither
the tested STAT3 target proteins nor STAT3-dependent reporter genes
were found to be induced. The reasons for this could be multiple.
IFNα-induced STAT3 phosphorylation e.g. failed to induce transcrip-
tional responses due to co-repressor complex SIN3 transcription regula-
tor homologue A (SIN3A) binding to STAT3 and suppressing STAT3-
mediated transcription [59]. In other studies the inefﬁcient STAT1 re-
sponse observed after IL-6 andOSM stimulation [60,61] has been attrib-
uted to the transient STAT1 phosphorylation [61–65] and additionally,
most of the phosphorylated STAT1 seemed to be present in STAT1/
STAT3 heterodimers, which translocated less efﬁciently into the nucleus
[60]. Such a mechanism might also occur for IL27. In addition, STAT1/3
heterodimers might not be able to activate STAT3-responsive genes in
an effective way.
When abrogating STAT1 or STAT3 expression by siRNA interference
we could show that IFNγ-induced STAT1 protein upregulation is un-
changed if STAT3 is knocked-down while the response is absent when
STAT1 is knocked down (Fig. 5). Thus, since IFNγ shows almost no de-
tectable STAT3 phosphorylation, the IFNγR cannot efﬁciently recruit
STAT3 in the case of a STAT1 knock-down. However, the case is very dif-
ferent for IL27. Since IL27 uses gp130 in its receptor complex, STAT1
knock-down transforms IL27 into an IL6-type cytokine, which leads to
recruitment and increased phosphorylation of STAT3 and an upregula-
tion of γ-ﬁbrinogen. Thus, knockdown of STAT1 is sufﬁcient to trans-
form the IFNγ-type response of IL27 into an IL6-type response while
STAT3 knock-down has little effects on IL27-induced STAT1 upregula-
tion. In contrast to this and as described before [42], abrogation of
STAT3 expression is sufﬁcient to transform the hy-IL6 response into an
interferon-type response. Thus, for IL6-type cytokines and IL27, absence
of either STAT3 or STAT1, respectively, leads to an opportunity for
“other” STATs, “normally” activated to a minor degree, to bind efﬁcient-
ly to the receptor complexes and to elicit transcription of their speciﬁc
target genes. Thus, knocking-down STATs to show their implication in
signalling pathways can potentially bemisleading. Depending on the af-
ﬁnities of different types of STATs for receptor phospho-tyrosine resi-
dues, signalling patterns can be changed drastically.
Sincewewere intrigued by the fact that IL27 almost totallymirrored
IFNγ responses in our microarray analysis, we also performed a micro-
array analysis in HepG2 cells in which STAT3 had been stably silenced
by shRNA to see more clearly what set of genes would not be induced
anymore. In these HepG2-shSTAT3 cells hy-IL6 stimulation elicited an
IFNγ-type response (Supplemental Fig. 5) in contrast to HepG2-shScr
control cells. Nevertheless, hy-IL6 still led to a signiﬁcant upregulation
of 13 typical IL6-dependent genes although the STAT3 phosphorylation
was reduced to 9–11% in HepG2-shSTAT3 compared to HepG2-shScr
AB
Fig. 6. IL6-type cytokine pre-stimulation inhibits a later IL27 response. A) HepG2, Hep3B and Huh7 cells were stimulated with OSM, hy-IL6, IL6, IFNγ, IFNα or IL27 as indicated. Western
blots were probed with antibodies against STAT1 and tubulin. Representative blots of three biological replicates are shown. B) HepG2, Hep3B and Huh7 cells were co-transfected with
either pcDNA5-SOCS3 and pGAS-TA-luc or pcDNA5 (empty vector) and pGAS-TA-luc. 24h after transfection, cells were stimulated with IL27 for 24h before lysates were prepared and
luciferase activity was measured. Luciferase activity is represented as % of IL27-stimulated signal for the control condition (pcDNA5 + pGAS-TA-luc). One representative experiment of
3 biological replicates – each performed in 9 technical replicates - is shown. Standard deviations are calculated from 9 technical replicates. Statistical analysis was performed as
decribed in materials and methods. ***: P b 0.001.
Fig. 7.
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a STAT3 phosphorylation of 19–35% of the hy-IL6 response in HepG2-
shScr. Most interestingly this much stronger response did not lead to a
signiﬁcant regulation of a single IL6-dependent gene. This might indi-
cate that STAT3 transcriptional activity in HepG2 upon stimulation
with IL27 could actively be prevented. A possible mechanismmight in-
clude STAT1 dependent expression of co-repressors complexes in anal-
ogy to what was described for IFNα [59], but many other mechanisms
are conceivable.
Our observations and the ones of others show that expression levels
of the various STATs in different cell lines could account for cell type-
speciﬁc differences that are observed concerning the different STAT fac-
tor contributions [46,51,52]. In addition, dynamic stimuli-dependent
changes in expression levels of the different STATs can alter the STAT ac-
tivation pattern of a given cytokine in one and the same cell type. E.g. in
NK cells IFNαwas described to activate STAT4,which these cells express
at high levels, and which in turn enhances the STAT1 levels, so that the
canonical STAT1/STAT2 signaling pattern emerges upon enhanced
STAT1 expression [66].
Concerning IL27 signalling, STAT3 was shown to be important for
regulating transcriptional output in activated CD4+ T cells, and to up-
regulate signiﬁcant numbers of STAT3-speciﬁc genes [46,51,52]. In con-
trast to what we ﬁnd, IL27 induced a STAT3 phosphorylationwhichwas
comparable in strength and duration to the IL6 response, and the STAT3
phosphorylation was not enhanced in STAT1−/− cells. Thus, in T cells
STAT3 activation upon IL27 seems to be intrinsically more efﬁcient
concerning the intensity and duration of STAT3 phosphorylation. This
could be dependent on STAT factor expression levels but also on those
of negative regulators, such as SOCS proteins or phosphatases. In T
cells STAT3 homodimers are also found in EMSA, which we could not
see in hepatic cells [18,51]. Our results in hepatocytes, however, show
that the IL27 responses in HCC lines and hepatocytes are mainly
STAT1-mediated and no signiﬁcant contribution of STAT3 to the tran-
scriptional response was detected.
Compared to hy-IL6 and OSM, IL27 and IFNγ only weakly and tran-
siently induce SOCS3 (Fig. 4B). Since IL27 uses gp130 as signalling re-
ceptor (which binds SOCS3 on the phosphorylated tyrosine 759 [44]),
we hypothesized that SOCS3 should be able to suppress IL27 responses
via binding to gp130. SOCS3 was shown to be upregulated STAT3-
dependently and to down-regulate IL6-type cytokine signalling but
not IFNγ signalling in vivo [67,68]. Interestingly, IL6-type cytokine
pre-stimulation (4 h), which induces SOCS3 expression, can suppress
a subsequent IL27-dependent STAT1 protein upregulation (Fig. 6A).
Heterologous expression of SOCS3 was sufﬁcient to mimic the IL6-pre-
stimulation effect on STAT1-dependent reporter gene constructs upon
IL27 stimulation (Fig. 6B). Thus, IL27 responses are susceptible to
cross-inhibition by e.g. pro-inﬂammatory IL6-type cytokines, which is
very likely mediated by STAT3-driven SOCS3 expression (Fig. 7). IFNγ
and IFNα seem less susceptible to this type of cross-inhibition. Thus, al-
though IL27 responses in HCC are almost identical to those observed
upon IFNγ stimulation, IL27 is still different from IFNγ by the fact that
its IFNγ-like activity can be dampened in the inﬂammatory context of
IL6-type cytokine stimulation. Since IL27 is capable of exerting anti-
tumour effects and is discussed as a candidate cytokine for enhancing
anti-tumour immune responses [69–76], one has to keep in mind that
a considerable reduction of its efﬁcacy might occur in tumours with
high levels of STAT3 activating cytokines.
Taken together, we have shown that IL27 behaves like a IFNγ-like
cytokine in liver cells. However, under certain conditions, IL27 may re-
veal its hidden characteristics of a typical IL6-type cytokine family
member: it can induce STAT3 targets (if STAT1 expression is very
low), and its signaling is susceptible to inhibition by SOCS3 (if
expressed, e. g. upon pre-stimulation with other members of the IL-6
family). It will be interesting to further elucidate how this ﬂexibility in
responses contributes to the various effects which have been attributed
to this cytokine. Moreover, a detailed knowledge of the spectrum of itsresponses needs to be taken into account when considering to use
IL27 in therapy as discussed [69–76].
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